drugset / Trial / NCT07600983
Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months (minimum 6 weeks) and older.
Timeline
- Start
- 2026-05-24
- Primary completion
- 2026-11-24
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pneumovax 23 | Vaccine | 0.5 ml | — |
| Comparator | Prevnar 13 | Vaccine | 0.5 ml | — |
| Subject | tetanus toxoid | Vaccine | 0.5 ml | — |